PH12015502691A1 - Use of high dose pridopidine for treating huntington's disease - Google Patents

Use of high dose pridopidine for treating huntington's disease

Info

Publication number
PH12015502691A1
PH12015502691A1 PH12015502691A PH12015502691A PH12015502691A1 PH 12015502691 A1 PH12015502691 A1 PH 12015502691A1 PH 12015502691 A PH12015502691 A PH 12015502691A PH 12015502691 A PH12015502691 A PH 12015502691A PH 12015502691 A1 PH12015502691 A1 PH 12015502691A1
Authority
PH
Philippines
Prior art keywords
pridopidine
disease
patient
high dose
huntington
Prior art date
Application number
PH12015502691A
Other languages
English (en)
Inventor
Bassan Merav
Eyal Eli
Hagai Esther Lukasiewicz
Sveinsdotter Teige Wickenberg Anna Kristina
Original Assignee
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52105289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12015502691(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceuticals Int Gmbh filed Critical Teva Pharmaceuticals Int Gmbh
Publication of PH12015502691A1 publication Critical patent/PH12015502691A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PH12015502691A 2013-06-21 2015-12-02 Use of high dose pridopidine for treating huntington's disease PH12015502691A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361837928P 2013-06-21 2013-06-21
US201361877832P 2013-09-13 2013-09-13
PCT/US2014/043204 WO2014205229A1 (en) 2013-06-21 2014-06-19 Use of high dose pridopidine for treating huntington's disease

Publications (1)

Publication Number Publication Date
PH12015502691A1 true PH12015502691A1 (en) 2016-03-14

Family

ID=52105289

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12015502691A PH12015502691A1 (en) 2013-06-21 2015-12-02 Use of high dose pridopidine for treating huntington's disease

Country Status (24)

Country Link
US (1) US10322119B2 (2)
EP (1) EP3010506B1 (2)
JP (1) JP2016523862A (2)
KR (1) KR102316933B1 (2)
CN (1) CN105592848A (2)
AU (1) AU2014281414A1 (2)
BR (1) BR112015029918A2 (2)
CA (1) CA2913781C (2)
CL (1) CL2015003690A1 (2)
DK (1) DK3010506T3 (2)
EA (1) EA201690069A1 (2)
ES (1) ES2879631T3 (2)
HK (1) HK1221646A1 (2)
HU (1) HUE054783T2 (2)
IL (1) IL242804B (2)
MX (1) MX384234B (2)
PE (2) PE20160195A1 (2)
PH (1) PH12015502691A1 (2)
PL (1) PL3010506T3 (2)
SG (1) SG11201509729YA (2)
TW (1) TW201529069A (2)
UA (1) UA122999C2 (2)
UY (1) UY35624A (2)
WO (1) WO2014205229A1 (2)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
TWI579272B (zh) 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
MX377576B (es) * 2014-01-22 2025-03-04 Prilenia Neurotherapeutics Ltd Formulaciones de pridopidina de liberación modificada.
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
MX2017008136A (es) 2014-12-22 2018-03-06 Teva Pharmaceuticals Int Gmbh Sal de l-tartrato de pridopidina.
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
JP6887952B2 (ja) 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
EP3324967A4 (en) * 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
JP7034488B2 (ja) 2016-02-24 2022-03-14 プリレニア・ニューロセラピューティクス・エルティーディー プリドピジンを使用する神経変性眼疾患の治療
EP4516356A3 (en) * 2016-08-24 2025-05-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
CA3035099C (en) 2016-08-24 2023-01-17 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating dystonias
CN109952100A (zh) 2016-09-15 2019-06-28 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗焦虑和抑郁的用途
HUE058314T2 (hu) 2016-09-16 2022-07-28 Prilenia Neurotherapeutics Ltd Pridopidin alkalmazása Rett-szindróma kezelésére
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
CA3050700C (en) 2017-01-20 2023-10-03 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile x syndrome
SI4154882T1 (sl) * 2017-08-14 2026-01-30 Prilenia Neurotherapeutics Ltd. Zdravljenje amiotrofične lateralne skleroze s pridopidinom
CA3073568A1 (en) * 2017-08-30 2019-03-07 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
JP2020533296A (ja) 2017-09-08 2020-11-19 プリレニア ニューロセラピューティクス リミテッド 薬物誘発性ジスキネジアを治療するためのプリドピジン
WO2020157083A1 (en) * 2019-01-31 2020-08-06 F. Hoffmann-La Roche Ag Assessing progression of huntington's disease
CN113395964A (zh) 2019-02-04 2021-09-14 普瑞尼亚神经治疗有限公司 用于帕金森氏病和与帕金森症相关的其它疾病的低剂量普利多匹定
CN121243170A (zh) * 2019-06-12 2026-01-02 普瑞尼亚神经治疗有限公司 用于治疗亨廷顿病及其症状的包含普利多匹定及其类似物的组合物
EP4030993B1 (en) * 2019-09-17 2026-04-15 F. Hoffmann-La Roche AG Improvements in personalized healthcare for patients with movement disorders
WO2022094565A1 (en) * 2020-10-28 2022-05-05 Buck Institute For Research On Aging N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating neurodegenerative disorders
WO2025181805A1 (en) * 2024-02-27 2025-09-04 Prilenia Neurotherapeutics Ltd. Pridopidine and sigma 2 antagonist agent for treating huntington disease and symptoms thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
EP1713486A4 (en) 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
CN101711236B (zh) 2007-04-12 2012-10-31 Nsab神经研究瑞典公司分公司 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物
US8669048B2 (en) 2008-06-24 2014-03-11 Parkinson's Institute Pluripotent cell lines and methods of use thereof
US8384755B2 (en) 2009-08-26 2013-02-26 Intouch Technologies, Inc. Portable remote presence robot
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
BR112014005389A8 (pt) 2011-09-07 2018-04-03 Ivax Int Gmbh Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
TWI579272B (zh) * 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
AU2013243461A1 (en) 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
US20150216850A1 (en) 2012-09-27 2015-08-06 Michael Hayden Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
MX2015003608A (es) 2012-09-27 2015-06-05 Teva Pharma Combinacion de laquinimod y pridopidina para tratar trastornos neurodegenerativos.
MX377576B (es) 2014-01-22 2025-03-04 Prilenia Neurotherapeutics Ltd Formulaciones de pridopidina de liberación modificada.
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
MX2017008136A (es) 2014-12-22 2018-03-06 Teva Pharmaceuticals Int Gmbh Sal de l-tartrato de pridopidina.
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
JP6887952B2 (ja) 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
EP3324967A4 (en) 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
CA3035099C (en) 2016-08-24 2023-01-17 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating dystonias
EP4516356A3 (en) 2016-08-24 2025-05-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
CN109952100A (zh) 2016-09-15 2019-06-28 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗焦虑和抑郁的用途
HUE058314T2 (hu) 2016-09-16 2022-07-28 Prilenia Neurotherapeutics Ltd Pridopidin alkalmazása Rett-szindróma kezelésére
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia

Also Published As

Publication number Publication date
EA201690069A1 (ru) 2016-06-30
PE20160195A1 (es) 2016-05-14
MX2015017307A (es) 2016-08-03
US10322119B2 (en) 2019-06-18
TW201529069A (zh) 2015-08-01
PE20170302A1 (es) 2017-03-31
KR20160055122A (ko) 2016-05-17
AU2014281414A1 (en) 2016-01-21
DK3010506T3 (da) 2021-07-12
HUE054783T2 (hu) 2021-09-28
SG11201509729YA (en) 2015-12-30
WO2014205229A8 (en) 2015-04-09
EP3010506A4 (en) 2017-02-08
UY35624A (es) 2015-01-30
CA2913781A1 (en) 2014-12-24
KR102316933B1 (ko) 2021-10-26
CL2015003690A1 (es) 2016-10-28
MX384234B (es) 2025-03-14
JP2016523862A (ja) 2016-08-12
WO2014205229A1 (en) 2014-12-24
PL3010506T3 (pl) 2021-11-02
IL242804B (en) 2022-02-01
EP3010506A1 (en) 2016-04-27
CA2913781C (en) 2022-05-10
BR112015029918A2 (pt) 2017-07-25
ES2879631T3 (es) 2021-11-22
EP3010506B1 (en) 2021-05-12
HK1221646A1 (zh) 2017-06-09
UA122999C2 (uk) 2021-02-03
CN105592848A (zh) 2016-05-18
US20140378508A1 (en) 2014-12-25

Similar Documents

Publication Publication Date Title
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2021002321A (es) Nuevos metodos.
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
MX377576B (es) Formulaciones de pridopidina de liberación modificada.
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
BR112015018168A2 (pt) inibidores de rock suaves
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
EP3970712A3 (en) Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
PH12016502352A1 (en) Pharmaceutical composition
MY204827A (en) Semaglutide in medical therapy
ZA202000028B (en) Use of vibegron to treat overactive bladder
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага
HK1225969A1 (zh) 利用低剂量的拉喹莫德治疗克隆氏病
EA201592261A1 (ru) Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности
IN2013MU01154A (2)